26 February 2021 - Evrysdi is approved in seven countries, submitted in 30 more.
Roche today announced that the EMA CHMP has recommended the approval of Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.